Cite
HARVARD Citation
Delimpasi, S. et al. (2022). Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. American journal of hematology. 97 (3), pp. E83-E86. [Online].